Vertex Pharmaceuticals (Europe) Ltd 4
4 · CRISPR Therapeutics AG · Filed Dec 26, 2018
Insider Transaction Report
Form 4
Vertex Pharmaceuticals (Europe) Ltd
10% Owner
Transactions
- Purchase
Common Shares
2018-12-24$22.91/sh+2,603$59,647→ 5,275,345 total - Purchase
Common Shares
2018-12-21$22.58/sh+22,742$513,478→ 5,272,742 total - Purchase
Common Shares
2018-12-24$23.18/sh+11,742$272,140→ 5,287,087 total - Purchase
Common Shares
2018-12-24$24.97/sh+53,655$1,339,696→ 5,340,742 total
Footnotes (5)
- [F1]Shares are directly held by Vertex Pharmaceuticals (Europe) Limited ("Vertex Europe"). Vertex Europe is an indirect wholly owned subsidiary of Vertex Pharmaceuticals Inc. Vertex Pharmaceuticals Inc. may be deemed to beneficially own the shares owned directly by Vertex Europe.
- [F2]Represents the weighted average price. These shares were purchased in multiple transactions at prices ranging from $22.46 and $22.70.
- [F3]Represents the weighted average price. These shares were purchased in multiple transactions at prices ranging from $22.69 and $23.00.
- [F4]Represents the weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.02 and $23.25.
- [F5]Represents the weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.82 and $25.00.